

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16. (Cancelled)

17. (Previously presented) A combination for site-specifically transforming cells *in vivo* comprising a catheter and a nucleic acid comprising a gene encoding p21.

18. (Cancelled)

19. (Previously presented) The combination of claim 17, wherein the catheter is a double balloon catheter.

20. (Previously presented) The combination of claim 17, further comprising a pharmaceutical carrier.

21. (Currently amended) The combination of claim 20, wherein the pharmaceutical carrier comprises a the nucleic acid.

22. (Previously presented) The combination of claim 17, wherein the nucleic acid is an expression vector.

23. (Previously presented) The combination of claim 22, wherein the expression vector comprises a viral promoter.

24. (Previously presented) The combination of claim 23, wherein the viral promoter is a CMV promoter.

25. (Previously presented) The combination of claim 23, wherein the viral promoter is a RSV promoter.

26. (Previously presented) The combination of claim 17, wherein a viral particle comprises the nucleic acid.

27. (Previously presented) The combination of claim 26, wherein the viral particle is an adenovirus particle.

28. (Previously presented) The combination of claim 26, wherein the viral particle is a retrovirus particle.

29. (Previously presented) The combination of claim 17, further comprising a liposome.

30. (Previously presented) The combination of claim 29, wherein the liposome comprises the nucleic acid.

31. (Previously presented) The combination of claim 17, wherein the nucleic acid comprises a second gene.

32. (Previously presented) The combination of claim 31, wherein the second gene encodes HLA-B7, an immunotherapeutic agent, cytokine, or prodrug converting enzyme.

33. (Previously presented) The combination of claim 32, wherein the prodrug converting enzyme is thymidine kinase.

34. (Previously presented) The combination of claim 31, wherein the gene encoding p21 and the second gene are operatively linked.

35. (Currently amended) The combination of claim 34, wherein the gene encoding p21 and the second gene are operatively linked such that they ~~form~~ encode a fusion protein.

36. (Currently amended) The combination of claim 35, wherein the ~~gene encoding the fusion protein~~ is a p21-thymidine kinase fusion protein.

Application Number 09/663,889

37-54. (Cancelled)